The aim of this study is to investigate the frequency and implications of pulmonary hypertension in lung cancer patients. To do so, data will be collected from all lung cancer patients at the university hospital Giessen. All data will be analyzed for possible hints of pulmonary hypertension as a comorbidity in lung cancer patients. All information will be generated from the regular guidelines based course of treatment and there will be no interventions. This study will serve as a prospective register for all lung cancer patients treated at the university hospital Giessen.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Pulmonary function test measured via Spirometry.
Timeframe: 2 years
sPAP values measured via Echocardiography.
Timeframe: 2 years
Body mass index.
Timeframe: 2 years
Overall Survival and Progression Free Survival measured in days.
Timeframe: 2 years
Measurements of the pulmonary artery diameter (PA) and ascending aorta (AA) diameter measured via computed tomography scan. PA and AA will be measured in millimeters.
Timeframe: 2 years
6 Minute Walk Test in meters.
Timeframe: 2 years
Modified Medical Research Council Scale (mMRC).
Timeframe: 2 years
chronic obstructive pulmonary disease assessment test (CAT).
Timeframe: 2 years